Dasabuvir
Sponsors
AbbVie, Valme University Hospital, Nova Scotia Health Authority, Kirby Institute, University of Modena and Reggio Emilia
Conditions
Chronic Hepatitis CChronic Hepatitis C InfectionChronic Hepatitis C Virus (HCV) InfectionChronic Hepatitis C, Genotype 1 or 4Chronic Hepatitis, C VirusCompensated CirrhosisDecompensated CirrhosisEnd-stage Renal Disease
Phase 2
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
CompletedNCT02486406
Start: 2015-10-28End: 2020-11-19Updated: 2021-10-05
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
CompletedNCT02493855
Start: 2015-06-30End: 2016-12-31Updated: 2017-10-31
Phase 3
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
CompletedNCT02207088
Start: 2014-09-23End: 2016-12-06Updated: 2017-11-09
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
CompletedNCT02216422
Start: 2014-09-30End: 2015-12-31Updated: 2016-06-29
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
CompletedNCT02219503
Start: 2014-09-30End: 2015-09-30Updated: 2021-07-12
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
CompletedNCT02219477
Start: 2014-11-24End: 2017-03-03Updated: 2017-07-11
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
CompletedNCT02476617
Start: 2015-06-30End: 2016-12-31Updated: 2017-10-03
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
CompletedNCT02582632
Start: 2015-11-24End: 2016-12-01Updated: 2021-07-30
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
CompletedNCT02634008
Start: 2016-06-30End: 2021-04-30Updated: 2022-08-22
Phase 4
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
Active, not recruitingNCT02460133
Start: 2015-07-10End: 2025-10-31Updated: 2024-08-23
Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.
NCT02950870
Start: 2016-12-31End: 2019-12-31Target: 75Updated: 2016-11-01
Unknown Phase
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
CompletedNCT02333292
Start: 2014-12-31End: 2017-06-30Updated: 2022-06-29
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
CompletedNCT02581163
Start: 2015-10-07End: 2018-02-12Updated: 2019-05-06
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
CompletedNCT02581189
Start: 2015-10-13End: 2017-12-20Updated: 2019-03-27
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
CompletedNCT02582671
Start: 2015-11-05End: 2017-11-29Updated: 2019-05-06
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
CompletedNCT02725866
Start: 2016-04-05End: 2017-10-31Updated: 2019-03-15
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
CompletedNCT02803138
Start: 2016-07-07End: 2018-10-21Updated: 2019-10-11